Clinical value of minor responses after 4 doses of rituximab in Waldenström macroglobulinaemia: a follow‐up of the Eastern Cooperative Oncology Group E3A98 trial
Open Access
- 6 November 2009
- journal article
- research article
- Published by Wiley in British Journal of Haematology
- Vol. 147 (5), 677-680
- https://doi.org/10.1111/j.1365-2141.2009.07892.x
Abstract
Waldenström macroglobulinaemia is a low‐grade, lymphoplasmacytic lymphoma that is responsive to rituximab. We report the role of a minor response in predicting overall outcomes. We extended follow‐up of a previously described cohort (n = 69) treated with 4 weekly doses of rituximab and observed durable responses (median time to progression, 30 months; 5‐year survival rate, 66%). Patients achieving a minor response [25–50% immunoglobulin M (IgM) reduction] appeared to do as well as those achieving an objective response (>50% IgM reduction), which suggests that more aggressive or intensive therapy for minor responders is not required. Future studies of Waldenström macroglobulinaemia should report minor responses because they are associated with clinically meaningful benefits. This trial was registered at http://www.clinicaltrials.gov as #NCT00005609.This publication has 13 references indexed in Scilit:
- Long-term survival in Waldenstrom macroglobulinemia: 10-year follow-up of Southwest Oncology Group–directed intergroup trial S9003Blood, 2009
- Waldenström macroglobulinaemiaBritish Journal of Haematology, 2007
- Update on treatment recommendations from the Third International Workshop on Waldenstrom's MacroglobulinemiaBlood, 2006
- Update on Recommendations for Assessing Response from the Third International Workshop on Waldenström's MacroglobulinemiaClinical Lymphoma Myeloma and Leukemia, 2006
- Extended rituximab therapy in Waldenström's macroglobulinemiaAnnals of Oncology, 2005
- Multicenter Phase 2 Trial of Rituximab for Waldenström Macroglobulinemia (WM): An Eastern Cooperative Oncology Group Study (E3A98)Leukemia & Lymphoma, 2004
- Treatment of Waldenstrom's Macroglobulinemia with Rituximab: Prognostic Factors for Response and ProgressionLeukemia & Lymphoma, 2004
- Prognostic factors and response to fludarabine therapy in Waldenstrom's macroglobulinemia: An update of a US intergroup trial (SW0G S9003)Seminars in Oncology, 2003
- Treatment recommendations in Waldenstrom's macroglobulinemia: Consensus Panel Recommendations from the Second International Workshop on Waldenstrom's MacroglobulinemiaSeminars in Oncology, 2003
- Uniform response criteria in Waldenstrom's macroglobulinemia: Consensus Panel Recommendations from the Second International Workshop on Waldenstrom's MacroglobulinemiaSeminars in Oncology, 2003